Global Market for Inhaled Drugs Rapidly Growing

"Around the world, the incidences of diseases like chronic pulmonary obstructive disease (COPD) and asthma are on the rise," explained Mark Marek, host of the Stock Radio. "That's boosting revenues for companies with existing billion-dollar inhaled drugs -- and bringing important new opportunities for companies with innovative new approaches."

The information compiled by the Stock Radio shows that three inhaled drugs are among the top 20 best-selling drugs world-wide. 

GlaxoSmithKline's Advair bronchodilator for asthma and chronic obstructive pulmonary disease (COPD) is the top-selling inhaled drug, with $4.8 billion in annual sales in the U.S., and $6.7 billion globally, in 2014. Next is Boehringer Ingelheim's Spiriva, which brought in $3.3 billion in the U.S. and $4.7 billion globally, followed by Symbicort from AstraZeneca, with $2.2 billion in U.S. sales and $4.2 billion worldwide.

The markets for these brand-name drugs and others are projected to grow rapidly over the next decade as the incidence of COPD and other diseases increases. Perhaps not surprising, there also is a large and growing market for generic competitors. A recent report from Transparency Market Research forecasts that the global market for generic inhalation and nasal spray drugs will jump from $21.8 billion in 2014 to $35.5 billion by 2023.

Most exciting, however, is the development of innovative new approaches for improving the efficiency of delivering drugs to the lungs, Stock Radio's research shows. A new report by Grand View Research explains that "technological advancements such as particle engineering... are expected to boost the market growth further." In particular, the new report says, "dry powder inhalers are expected to be the fastest growing segment owing to factors such as advancements in formulating technology."

Stock Radio's research has uncovered one specific example that illustrates all these trends. Generic drug giant Mylan is now working with a small Boston-based pharmaceutical company named Pulmatrix, Inc. (NASDAQ: PULM) to develop a co-branded generic equivalent to Boehringer Ingelheim's Spiriva, using a novel dry powder formulation developed by Pulmatrix that improves the efficiency of drug delivery.

One of the nation's top investment newsletters covering small-cap stocks, the KonLin Letter, has already recognized the potential for this product and others from Pulmatrix. In a recent Stock Radio interview, Konrad Kuhn, editor and publisher of the KonLin Letter, explained why he named Pulmatrix his "#1 Stock Pick of the Year."

About Pulmatrix

Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The company's proprietary product pipeline is focused on advancing treatments for lung diseases, including  opportunities in major pulmonary diseases through collaborations, like PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease (COPD) and PUR1900, an inhaled antifungal that could benefit severe asthmatics and patients with rare disease like cystic fibrosis.  Pulmatrix's product candidates are based on iSPERSE™, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.

About TheStockRadio.com

TheStockRadio.com is a small-cap research and investment commentary provider. TheStockRadio.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information and full disclosure on TheStockRadio please visit http://thestockradio.com

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

Contact:

Mark Marek
The Stock Radio
http://theStockRadio.com
+44-7821873346

Video - http://youtu.be/t8RgU8YUtjo

SOURCE TheStockRadio.com